Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd has signed a strategic cooperation agreement with Guangdong Raffles Pharmaceutical Technology Co., Ltd and announced further in-depth cooperation in API process optimization, clinical sample preparation and new drugs commercial production.

From September 11 to 12, 2019, Shenzhen International Biopharmaceutical Industry Innovation & Development Summit 2019 was successfully held at Shenzhen Yanzi Lake International Convention and Exhibition Center.

Guangdong Zhongsheng Raynovent Biotechnology Co., Ltd. held the national investigators conference of phase 2 clinical trial of ZSP1273 to treat Influenza A in Guangzhou, which marked the official initiation of phase 2 trial of ZSP1273, a new drug developed by Raynovent for the treatment and prevention of influenza A and human avian influenza.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by the National Intellectual Property Administration, People's Republic of China.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by Federal Service for Intellectual Property (Russia).